

Case Series of Covid-19 Infections with Fourth Dose of Bivalent Mrna Vaccine in The Period from October 2022 to October 2023 in A General Medicine Office of Toledo (Spain)

Jose Luis Turabian

Specialist in Family and Community Medicine Health Center Santa Maria de Benquerencia. Regional Health Service of Castilla-la Mancha (SESCAM), Toledo, Spain.

***Corresponding Author:** Jose Luis Turabian, Specialist in Family and Community Medicine Health Center Santa Maria de Benquerencia. Regional Health Service of Castilla-la Mancha (SESCAM), Toledo, Spain.

Received date: November 22, 2023; **Accepted date:** December 14, 2023; **Published date:** January 10, 2024

Citation: Jose L. Turabian (2024), Case Series of Covid-19 Infections with Fourth Dose of Bivalent Mrna Vaccine in The Period from October 2022 to October 2023 in A General Medicine Office of Toledo (Spain), *Clinical Research and Clinical Trials*, 9(1); DOI:10.31579/2693-4779/170

Copyright: © 2024, Jose Luis Turabian. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract:

Background

The effectiveness of administering booster doses with vaccines adapted to new variants and subvariants is still a matter of debate.

Objective

To describe the cases of covid-19 infections in vaccinated people with 4th dose.

Methodology

An observational, longitudinal and prospective case series study of adult patients with covid-19 infections in vaccinated people with 4th dose in general medicine from October 1, 2022 to October 1, 2023. Descriptive epidemiological analysis considered a set of selected demographic and clinical features.

Results

21 covid-19 infections were included in vaccinated people with 4th dose from October 2022 to October 2023. The main characteristics were: 67% >= 65 years, 62% women, 24% Socio-Health Care Workers, 9% with Moderate-severe severity (hypoxia, pneumonia), 86% had Chronic diseases [mainly Circulatory system (22%) and Endocrine (20%)]. There were practically no psychosocial risk factors [Complex family/ Problems in the family context, Low-income household, Ethnic minority (5, 0% and 0% respectively)], and 24% were re-infections. General symptoms (discomfort, asthenia, myalgia, fever, arthralgia) (42%) and Respiratory symptoms (cough, dyspnea, chest pain) (31%) predominated.

Conclusion

In our series from October 2022 to October 2023, in the context of a general medicine consultation in Toledo (Spain), the risk profile of the cases, the frequency of reinfections and the infrequency of severity, suggests that revaccination is still advisable in vulnerable people such as older people, women, socio-health care workers and chronically ill people.

Keywords: covid-19; sars-cov-2; epidemiological characteristic; symptoms; case series; general practice

Introduction

Since March 2020, when the World Health Organization declared the state of pandemic for the coronavirus disease 2019 (covid-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it has evolved in several periods of different duration and repercussions in terms of morbidity and mortality (1). One of the determinants of morbidity and mortality has been the behavior of the virus during the pandemic from the

original strain (Wuhan-alpha) to the currently predominant Omicron. Said behavior of the virus, in addition to the health measures implemented, especially vaccination, explain the differences between the pandemic and currently endemic period with respect to symptomatic infection, morbidity and deaths (2-4).

Currently, the predominant variant in Spain is Omicron, which has a greater immune escape capacity than previous variants, is more transmissible and has less severity. It comprises five lineages-mutations: BA.1, BA.2, BA.3, BA.4 and BA.5. So far, no differences in the severity of the cases have been observed for any of them. Currently, the BA.5 variant is the dominant one (5). In Spain, from the beginning of vaccination until September 14, 2022, 93% of citizens over 12 years of age had the complete vaccination schedule (6). The Health Authorities decided to start vaccinating the fourth dose to people over 80 years of age and institutionalized with a bivalent vaccine available. Depending on the availability of vaccines, it was extended to people over 60 years of age, immunosuppressed people, social health workers and pregnant women, and finally rest of population (7).

The previous monovalent boosters had managed to recover vaccine effectiveness up to 85-90% against hospitalization and death, which had decreased over the months and coinciding with the circulation of the Omicron variant and its immune evasion (8). For the second booster (fourth dose) bivalent vaccines were used (9). Since September 1, 2022, the European Commission and the European Medicines Agency (EMA) authorized the use of the adapted covid-19 vaccines Comirnaty Original/Omicron BA.1 and Spikevax bivalent Original/Omicron BA.1, as vaccines for a second booster dose in people over 12 years of age with the complete primary vaccination schedule and at least 3 months after the last dose of vaccine administered. Likewise, the EMA approved the adapted bivalent covid-19 vaccine Comirnaty Original/Omicron BA.4- BA.5 for use in people over 12 years of age who have received at least one primary cycle of vaccination against covid-19 (10, 11).

With the adaptation of vaccines, the aim was to expand protection against different variants. Predictive studies of the efficacy of bivalent boosters in the vaccinated population concluded that protection against serious infection rose from 50% to 87% with monovalent booster, while it would reach 98% when using bivalent booster. Furthermore, the lower the preboost immunity, the greater the relative benefit of a bivalent booster would be (12). Its approval was based on clinical data available with Comirnaty Original/Omicron BA.1 and laboratory immunogenicity studies. Studies showed that the bivalent vaccine can trigger strong immune responses against Omicron BA.1 and the original SARS-CoV-2 strain in previously vaccinated people, and greater responses against subvariant BA.1 than the original vaccines (13).

However, applying a fourth dose in general population has the disadvantages that it can lead to low vaccine coverage due to pandemic fatigue, and that repetition with new doses can cause a phenomenon of immune tolerance. A repeat dose of the bivalent BA.5 mRNA vaccine, as recommended for some populations, may not be sufficient to broaden neutralizing antibody responses and overcome immunological imprinting in elderly but healthy individuals (14).

In this changing scenario, where clinical studies are still ongoing, and where epidemiological surveillance has been greatly reduced, causing a lack of data regarding many population groups (2, 15, 16), sustained clinical-epidemiological surveillance are needed, which could include longitudinal cohort studies. In this context, we present an observational, longitudinal and prospective case series study of adult patients with covid-19 infections in vaccinated people with 4th dose in general medicine from October 1, 2022 to October 1, 2023.

Material and Methods

Design and emplacement

An observational, longitudinal and prospective study of Covid-19 infections in vaccinated people with 4th dose was conducted from October 1, 2022 to October 1, 2023, in a general medicine office in Toledo, Spain, which has a list of 2,000 patients > 14 years of age (in Spain, the general practitioners [GPs] care for people > 14 years of age, except for exceptions requested by the child's family and accepted by the GP). The GPs in Spain work within

the National Health System, which is public in nature, and are the gateway for all patients to the system, and each person is assigned a GP (17). Data from this series of cases were previously published from a shorter period of time than that of the current study, and global data on all covid infections in people with and without a fourth dose of vaccination (18-20).

Outcome of interest

To describe the cases of covid-19 infections in vaccinated people with 4th dose.

Diagnosis of covid-19

The diagnosis was performed with reverse transcriptase polymerase chain reaction oropharyngeal swab tests or antigen testing (21) performed in health services or at home.

Collected variables

The following variables were collected:

-Age and sex

-Chronic diseases (defined as "any alteration or deviation from normal that has one or more of the following characteristics: is permanent, leaves residual impairment, is caused by a non-reversible pathological alteration, requires special training of the patient for rehabilitation, and / or can be expected to require a long period of control, observation or treatment" (22), classified according to the International Statistical Classification of Diseases and Health-Related Problems, CD-10 Version: 2019 (23)

-If they were Health Care Workers

-Problems in the family context and low-income household based on the genogram and in the experience of the GP for their continuity of care and knowledge of the family (genogram is a schematic model of the structure and processes of a family, which included the family structure, life cycle and family relational patterns. It was understood that "complex" genograms present families with psychosocial problems) (24, 25)

-Ethnic minority (defined as a "human group with cultural, linguistic, racial values and geographical origin, numerically inferior compared to the majority group") (26)

-Disease severity (classified according to: 1. mild cases: clinical symptoms are mild and no manifestation of pneumonia can be found on images; 2. moderate cases: with symptoms such as fever and respiratory tract symptoms and the manifestation of pneumonia can be seen on the imaging tests; and 3. severe cases: respiratory distress, respiratory rate ≥ 30 breaths / min., pulse oxygen saturation $\leq 93\%$ with room air at rest, arterial partial pressure of oxygen / oxygen concentration ≤ 300 mmHg.) (27); to simplify comparison, moderate and severe cases were counted together;

-Date of covid-19 infection diagnosis

-Presence of reinfection (SARS-CoV-2 reinfection was conventionally defined as a documented infection occurring at least 90 days after a previous infection) (28, 29)

-Vaccination status against covid-19 at the date of acute infection: vaccinated with fourth dose (second booster) for fall-winter 2022 (30)

Epidemiological analysis

Descriptive epidemiological analysis considered a set of selected demographic and clinical features. Excessive fragmentation of the data was avoided to avoid showing a small number of cases. The age of 65 years was used as the beginning of old age (31)

Ethical issues

No personal data of the patients were used, but only group results, which were taken from the clinical history.

Results

21 covid-19 infections were included in vaccinated people with 4th dose from October 2022 October 2023. The main characteristics were: 67% > = 65 years, 62% women, 24% Socio-Health Care Workers, 9% with Moderate-severe severity (hypoxia, pneumonia), 86% had Chronic diseases [mainly

Circulatory system (22%) and Endocrine (20%)]. There were practically no psychosocial risk factors [Complex family/ Problems in the family context, Low-income household, Ethnic minority (5, 0% and 0% respectively)], and 24% were re-infections. General symptoms (discomfort, asthenia, myalgia, fever, arthralgia) (42%) and Respiratory symptoms (cough, dyspnea, chest pain) (31%) predominated (TABLE 1, TABLE 2, TABLE 3).

VARIABLES	COVID-19 INFECTIONS IN VACCINATED PEOPLE WITH 4TH DOSE FROM OCTOBER 2022 OCTOBER 2023 N= 21
> = 65 years	14 (67)
= < 45 years	0
Women	13 (62)
Social-occupancy class of patients (people with some type of labor specialization)	7 (33)
Socio-Health Care Workers	5 (24)
Moderate-severe severity	2 (9) (hypoxia, pneumonia)
Chronic diseases	18 (86)
Complex family/ Problems in the family context	2 (9)
Low income household	0
Ethnic minority	0
Reinfection	5 (24)

(): Denotes percentages

Table 1: Selected Variables Of Covid-19 Infections In Vaccinated People With 4th Dose From October 2022 October 2023

SYMPTOMS COVID-19 INFECTION* ACCORDING TO WHO, ICD-10 GROUPS	COVID-19 INFECTIONS IN VACCINATED PEOPLE WITH 4TH DOSE FROM OCTOBER 2022 OCTOBER 2023 N= 21
General (discomfort, asthenia, myalgia, fever, arthralgias)	30 (42)
Respiratory (cough, dyspnea, chest pain)	22 (31)
ENT (anosmia / ageusia, odynophagia, rhinorrhea, pharyngeal dryness-mucus, epistaxis, ear pain)	11 (15)
Digestive (anorexia, nausea / vomiting, diarrhea, abdominal pain)	1 (1)
Neurological (headache, dizziness, mental confusion, dysarthria, disorientation, photopsia, syncope)	7 (10)
Psychiatric (aAnxiety, insomnia)	0
Skin (chilblains, flictenas, rash)	0
Urológico (dysuria, frequency)	1 (1)
Total, symptoms*	72 (100)

(): Denotes percentages; * Patients could have more than one symptom. The percentages are over the total of symptoms

Table 2: Symptoms of Covid-19 Infections In Vaccinated People With 4th Dose From October 2022 To October 2023

CHRONIC DISEASES* ACCORDING TO WHO, ICD-10 GROUPS	COVID-19 INFECTIONS IN VACCINATED PEOPLE WITH 4TH DOSE FROM OCTOBER 2022 OCTOBER 2023 N= 21
-I Infectious	0
-II Neoplasms	2 (3)
-III Diseases of the blood	3 (4)
-IV Endocrine	14 (20)
-V Mental	9 (13)
-VI-VIII Nervous and Senses	5 (7)
-IX Circulatory system	16 (22)
-X Respiratory system	2 (3)
-XI Digestive system	7 (10)
-XII Diseases of the skin	2 (3)
-XIII Musculo-skeletal	5 (7)
-XIV Genitourinary	6 (8)
TOTAL, chronic diseases*	71 (100)

(): Denotes percentages; *Patients could have more than one chronic disease. The percentages of chronic diseases are over the total of chronic diseases

Table 3: Chronic Diseases In Covid-19 Infections In Vaccinated People With 4th Dose In The Period From October 2022 To October 2023

Discussion

1. Main findings

The main results of our study were that the covid-19 infections in vaccinated people with 4th dose:

1. They predominated in people over 65 years of age, women, with chronic diseases of the Circulatory system and Endocrine, without psychosocial risk factors, and with a significant frequency in Socio-Health Care Workers.
2. The main symptoms were General (discomfort, asthenia, myalgia, fever, arthralgia) and Respiratory (cough, dyspnea, chest pain).
3. They mostly presented mild severity.
4. A quarter of these infections were re-infections.

From the first months of 2022, the Omicron variant was the dominant variant in Spain after having displaced the Delta variant (32). The predominant variants in Spain during 2023 were those of the XBB family. The XBB.1.5 lineage became dominant globally in February 2023 and in March in Spain. The “Eris” variant (EG.5), a descendant of the omicron, also of the XBB family, has spread rapidly since the end of July 2023 throughout the United States, Europe (including Spain) and Asia (5, 33-36).

On the other hand, covid-19 is at a tipping point, meaning that high levels of immunity to SARS-CoV-2 are beginning to limit its impact and reach. Currently, many countries do not test all symptomatic patients, nor do they systematically collect the number of cases or their clinical-epidemiological characteristics (16, 37). In Spain, the surveillance and control strategy against covid-19 after the acute phase of the pandemic, in force since March 28, 2022, indicates the need to perform PCR or antigen testing only in specific situations that fundamentally include people with vulnerability criteria, of vulnerable areas, and those that require hospital admission. The reported cases therefore represent these groups and not the total number of SARS-CoV-2 infections, so the evolution of the pandemic monitoring indicators must be adapted to this circumstance and the data from these reports cannot be compared with those of prior reports (38). In this situation, many people with symptoms in the community choose to perform individual

tests at home (39). But, frequently, people with a positive test at home do communicate this circumstance to their family doctor, to seek treatment and/or sick leave.

Taking into account these circumstances that contextualize our results, given the risk profile of the cases and the frequency of reinfections, and the infrequent severity of the infections, one can think about the usefulness of the fourth dose of vaccine; as well as the in its short duration. So, it would seem reasonable to continue advising revaccination of vulnerable people (the elderly, women, Health Care Workers and chronically ill patients).

2. Comparison with other studies

Vaccination provides substantial protection against both symptomatic and severe covid-19. However, there has been continued and substantial evolution of SARS-CoV-2 variants since the virus emerged, such as Omicron and its sub-variants, posing challenges for the public health response, including ensuring that vaccines continue to provide protection, which have markedly reduced efficacy in regimens based on the ancestral Wuhan variant. Thus, booster vaccination for the prevention of covid-19 is required to overcome this loss of protection (40, 41).

Since September 2022, Moderna and Pfizer-BioNTech bivalent SARS-CoV-2 vaccines containing equal amounts of spiked mRNA from the ancestral BA.4-BA.5 and omicron subvariants replaced their monovalent counterparts as booster doses for people over 12 years old. It is strongly suggested that a bivalent booster may preserve the safety and serological efficacy of the original monovalent booster while broadening the spectrum of antibody response, helping to restore protection that might have diminished since the last previous dose (42-49). This justifies the use of sequence-adapted vaccines (50-60). Thus, it has been reported that benefits of mRNA covid-19 vaccines in protecting against the omicron variant outweigh the risks, regardless of age, sex, and comorbidity (61).

Immunological profiles are increasingly heterogeneous (individuals who have been previously infected, or previously vaccinated with a primary series and/or booster doses on different platforms, with various spike protein antigens; as well as individuals who have been infected and then vaccinated, and individuals who have been vaccinated and then infected), so the

performance of an updated vaccine will vary depending on the nature and magnitude of the previously acquired immunity in each person (40). The continued circulation of SARS-CoV-2 in the current endemic period will manifest itself depending on reinfection rates, the availability and effectiveness of the vaccine, and the social, immune and innate factors that modulate the transmissibility of the virus (62). We found 24% of covid-19 re-infections were in vaccinated people with 4th dose.

Bivalent vaccine, a previous infection, or timely access to screening and treatment can help prevent the seriously cases from Covid-19. However, some people are more likely than others to become seriously ill from Covid-19. This includes older people or those who are immunocompromised, certain disabilities or underlying conditions (57, 60, 63, 64). We found that 67% of the covid-19 cases with the fourth dose of vaccine were \geq 65 years, and 86% had chronic diseases, mainly of the Circulatory system (22%) and Endocrine (20%).

Finally, in relation to psychosocial factors, understood as the risks to physical, mental, and social health generated by socioeconomic determinants, the employment condition, the organization and content of work and the relational factors that intervene in the psychological functioning, it is admitted that they influence cognitive, emotional, behavioral processes and, with regard to risk perception of covid-19 and vaccination with the fourth dose (65). In our study we did not find psychosocial risk factors in cases of covid-19 with the fourth dose.

Study limitations and strengths

1. The number of cases was small and thus the results may be subject to erroneous interpretations.
2. Asymptomatic patients were not included, since no screening intervention was performed
3. The great accessibility of patients to the family doctor, and the fact of the continuity of care that characterizes family medicine, suggest that the data presented correspond to the population reality.
4. It must be taken into account that case series studies only include "numerators" so they cannot be extrapolated to incidence rate values.

Conclusión

In our series from October 2022 October 2023, in the context of a general medicine consultation in Toledo (Spain), covid-19 infections in vaccinated people with 4th dose predominated in older women with chronic diseases of the Circulatory system and Endocrine; without psychosocial risk; with a significant frequency in Socio-Health Care Workers; with General symptoms (discomfort, asthenia, myalgia, fever, arthralgia) and Respiratory symptoms (cough, dyspnea, chest pain), with slight severity; and a quarter of these infections were re-infections. Given the risk profile of the cases, the frequency of reinfections, and the low frequency of severity, revaccination of vulnerable people (the elderly, women, Health Care Workers and chronically ill people) is still advisable.

References

1. Instituto de Salud Carlos III (2022) [Report No. 145. COVID-19 situation in Spain. COVID-19 Report.
2. Turabian JL (2023) Covid-19 endemicity and lack of epidemiological surveillance. Rapid-responses to Covid-19: Infections climb globally as EG.5 variant gains ground. *BMJ* 382: 1900.
3. Turabian JL (2023) Covid-19 Temporal Variations and Association with Risk Factors in Endemicity Time from October 2022 to October 2023, In A General Medicine Office, In Toledo (Spain): The Seasonal Pattern of Covid-19 Does Not Appear to Be Related to Climate Factors but to Human Activities. *J of Case Reports in Infectious Diseases and Viruses*; 1(1):01-08.
4. Turabian JL (2023) Endemicity, Seasonal Variations, Lack of

- Epidemiological Surveillance and General Practice in Covid-19. *J Cur Tre Inf Dis Res* 1(1): 1-3.
5. Ministerio de Sanidad (2022) [Update on the epidemiological situation of SARS-CoV-2 variants in Spain. September 6, 2022]. Disponible en: COVID19_Actualizacion_variantes_20220913.
6. Ministerio de Sanidad (2023) [Comprehensive management of COVID-19 vaccination]. GIV.
7. Ministerio de Sanidad (2022) [Vaccination recommendations against COVID-19 for autumn in Spain. Approved by the Public Health Commission on. Prepared by the Vaccination Program and Registry Presentation]. Consejo Interterritorial. Comisión de Salud Pública.
8. UpToDate (2023) [Vaccines for Covid-19].
9. Javierre Miranda AP, Aldaz Herce P, Gómez Marco JJ (2022) [Is the fourth dose justified for SARS-CoV-2? Between necessity and evidence]. *Aten Primaria*; 54(12).
10. EMA (2022) [First booster vaccines adapted against COVID-19 recommended for approval in the EU.01/09/2022]. Agencia Europea de Medicamentos (europa.eu). Vidal Vademecum Spain.
11. **CDE Almería (2022)** First adapted COVID-19 booster vaccines recommended for approval in the EU. European Commission.
12. Khoury DS, Docken SS, Subbarao K, et al. (2023) Predicting the efficacy of variant-modified COVID-19 vaccine boosters. *Nat Med*; 29: 574-8.
13. EMA. Agencia Europea del Medicamento (2022) Adapted vaccine targeting BA.4 and BA.5 Omicron variants and original SARS-CoV-2 recommended for approval.
14. Wang Q, Bowen A, Ho J, et al. (2023) SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. *Lancet*; 402(10415): 1827-8.
15. Charumilind S, Craven M, Lamb J, Sabow A, Singhal S, Wilson M (2022) When will the COVID-19 pandemic end? McKinsey & Company.
16. Turabian JL (2022) An ostrich strategy for covid-19 is too risky. *BMJ*; 377-1112.
17. Turabian JL (1995) [Notebooks of Family and Community Medicine. An introduction to the principles of Family Medicine]. Madrid: Díaz de Santos.
18. Turabian JL (2023). Incidence Rates of Covid-19 Re-Infection Are Lower in People with Fourth Dose Versus Without Fourth Dose of Bivalent mRNA. *J Pharma Interven*; 10.56391/JPI.
19. Turabian JL (2023) Risk Factors for Re-Infection of Covid-19 with Fourth Dose versus without Fourth Dose of Bivalent mRNA Covid-19 Vaccines. *Arch Health Sci*; 7(1): 1-11.
20. Turabian JL (2023) Clinical-Epidemiological Covid-19 Case Series Study in Endemic Period, from October 2022 to October 2023, in a General Medicine Office, in Toledo (Spain): Mild Symptoms should not Imply Mild Epidemiological Surveillance. *Int Jr Infect Dis & Epidemiology*; 4(2):1-6.
21. Ministerio de Sanidad (2021) [COVID-19 early detection, surveillance and control strategy.
22. Strauss AL (1984) Chronic illness and the quality of life. St Louis: The C.V. Mosby Company.
23. WHO. International Statistical Classification of Diseases and Health-Related Problems. ICD-10 Version: 2019.
24. Turabian JL (2017) Family Genogram in General Medicine: A Soft Technology that can be Strong. *Res Med Eng Sci*; 3(1).
25. Russell LT (2020) Capturing Family Complexity in Family Nursing Research and Practice. *J Fam Nurs*; 26(4):287-93.
26. Diccionario panhispánico del español jurídico (2022) [Ethnic minority].
27. Mao S, Huang T, Yuan H, et al. (2020) Epidemiological analysis of 67 local COVID-19 clusters in Sichuan Province, China.

- BMC Public Health; 20-1525
28. Slezak J, Bruxvoort K, Fischer H, Broder B, Ackerson B, Tartof S (2021) Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. *Clin Microbiol Infect*; 27(12): 1860.7-10.
 29. Altarawneh HN, Chemaitelly H, Ayoub Hh, et al. (2022) Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J Med*; 387(1): 21-34.
 30. 30.-Consejo Interterritorial (2022) [Update of the vaccination recommendations against COVID-19 for autumn-winter in Spain Approved by the Public Health Commission on December 15, 2022. Prepared by the Report on the Vaccination Program and Registry]. Sistema Nacional de Salud. España.
 31. Reijneveld SA, Gunning-Schepers LJ (1994) Age, socioeconomic status, and mortality at the aggregate level. *J Epidemiol Community Health*; 48: 146-50.
 32. Centro de Coordinación de Alertas y Emergencias Sanitarias (2022) [Update of the epidemiological situation of SARS-CoV-2 variants in Spain. May 03, 2022]. Ministerio de sanidad. España.
 33. Viciosa M (2023) [If you have covid today, the new variant O EG.5 or 'Eris' may have something to do with it (and it is not more serious)]. *Newtral*; 11 agosto.
 34. Pérez B (2023) [The new eris variant, more contagious, already alerts doctors to the rebound in covid]. *El Periódico*; 10 de agosto.
 35. Looi M (2023) Covid-19: Hospital admissions rise in England amid fears of new variant and waning immunity. *BMJ*; 382-1833.
 36. Smith DG (2023) What to Know About the New Dominant Covid Variant. EG.5 is spreading quickly, but experts say it's no more dangerous than previous versions. Another new variant, called BA.2.86, is being closely watched because of its mutations. *The New York Times*.
 37. Mayor SJ, Welte T (2023) From Pandemic to Endemic: How Do Influenza and SARS-CoV-2 Compare? *Medscape CME & EDUCATION*.
 38. Centro de Coordinación de Alertas y Emergencias Sanitarias (2023) [Update No. 672. Coronavirus disease (COVID-19). 06/30/2023]. Ministerio de Sanidad. España.
 39. Turabian JL (2023) Covid-19 infections with positive test at home versus in health services, in the period from October 2022 to October 2023, in the general medicine office, in Toledo (Spain). *Journal of Health Care and Research*. In Press.
 40. Grant R, Sacks JA, Abraham P, et al. (2023) When to update COVID-19 vaccine composition. *Nat Med*; 29, 776-80.
 41. Callaway E (2022) COVID 'variant soup' is making winter surges hard to predict. Descendants of Omicron are proliferating worldwide — and the same mutations are coming up again and again. *Nature*; 611: 213-4.
 42. Chalkias S, Harper C, Vrbicky K, et al. (2022) A bivalent Omicron-containing booster vaccine against Covid-19. *N Engl J Med*; 387: 1279-91.
 43. Cohen C, Pulliam J (2023) COVID-19 infection, reinfection, and the transition to endemicity. *Lancet*; 401(10379): 798–800.
 44. Lin D-Y, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z (2023) Durability of Bivalent Boosters against Omicron Subvariants. *N Engl J Med*.
 45. European Medicines Agency (2022) ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines.
 46. Jiménez AL (2022) [Portfolio of omicron-adapted vaccines expands: how does each one work? The EMA has already recommended the authorization of the vaccines against Covid-19 adapted from Comirnaty Original/Omicron BA.1, Spikevax bivalent Original/Omicron BA.1 and Comirnaty Original/Omicron BA.4-5]. *ConSalud.es*.
 47. Kingsley T (2022) UK 'blind' to new immune-evasive Covid variants creating 'perfect storm' for devastating wave.
 48. Lin D-Y, Gu Y, Xu Y, et al. (2022) Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. *JAMA*; 328: 1415-26.
 49. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G (2022) Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. *N Engl J Med*; 387:1332-3.
 50. Lin D-Y, Xu Y, Gu Y, et al. (2023) Effectiveness of Bivalent Boosters against Severe Omicron Infection. *N Engl J Med*; 388: 764-6.
 51. Winokur P, Gayed J, Fitz-Patrick D, et al. (2023) Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years. *N Engl J Med*; 388:214-27.
 52. Loewy MA (2023) [COVID-19: the weekly summary (January 6-12, 2023)]. *Medscape* 13 de enero.
 53. Doheny K (2023) What's Next for COVID? Here's What to Know. *Medscape*; Jan 03.
 54. Marks PW, Califf RM (2023) Bivalent Covid-19 Vaccines. *N Engl J Med*; 388: 1151-2.
 55. Zou J, Kurhade C, Patel S, et al. (2023) Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. *N Engl J Med*; 388: 854-7.
 56. Davis-Gardner ME, Lai L, Wali B, et al. (2022) Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. *N Engl J Med*; 388: 183-5.
 57. Roa R (2022) [The second booster dose protects well at 6 months]. *La biblioteca de Springfield*.
 58. Ferdinands JM, Rao S, Dixon BE, et al. (2022) Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. *BMJ*; 379: e072141
 59. Loewy MA (2022) [COVID-19: the weekly summary (September 30 to October 6, 2022)]. *Medscape*; 7 de oct.
 60. Roa R (2022) [Fourth dose of Covid-19 vaccine]. *La biblioteca de Springfield*.
 61. Kitano T, Thompson DA, Engineer L, Dudley MZ, Salmon DA (2023) Risk and Benefit of mRNA COVID-19 Vaccines for the Omicron Variant by Age, Sex, and Presence of Comorbidity: A Quality-Adjusted Life Years Analysis. *Am J Epidemiol*; 192(7): 1137-47.
 62. Shaman J, Galanti M (2020) Will SARS-CoV-2 become endemic? *Science*; 30 OCT: 527-9.
 63. CDC (2023) Factors That Affect Your Risk of Getting Very Sick from COVID-19 Updated May 11, 2023. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.
 64. Adams K, Rhoads JP, Surie D, et al. (2022) Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. *BMJ*; 379-072065
 65. Pereyra G, Gulli S, Lopez Escobar LT, Ponce Reberte S (2021) [Psychosocial factors that affect the perception and behaviors of the Argentine population regarding vaccination against COVID 19]. XIII Congreso Internacional de Investigación y Práctica Profesional en Psicología. Universidad de Buenos Aires, Buenos Aires.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Manuscript](#)

DOI: [10.31579/2693-4779/170](https://doi.org/10.31579/2693-4779/170)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/clinical-research-and-clinical-trials>